Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan

Table 4 Unadjusted and adjusted HR for treatment modification stratified by drug category

Second-line combination drug	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Fixed combination
PGA/BB
Latanoprost/ Timolol maleate	1.377 (0.959 1.977)	0.0832	1.322 (0.83 2.106)	0.2397
Travoprost/ Timolol maleate	0.670 (0.477 0.941)	0.0208	0.578 (0.377 0.886)	0.0119
CAI/BB
Brinzolamide/ Timolol maleate	0.852 (0.499 1.453)	0.5561	0.802 (0.394 1.631)	0.5418
Dorzolamide hydrochloride/ Timolol maleate	0.998 (0.751 1.326)	0.9867	0.862 (0.6 1.238)	0.4211
Unfixed combination
PGA	0.527 (0.404 0.687)	< 0.0001	0.549 (0.39 0.771)	0.0006
CAI	3.077 (1.721 5.502)	0.0002	3.603 (1.77 7.334)	0.0004
BB	1.867 (1.388 2.513)	< 0.0001	2.014 (1.386 2.926)	0.0002
Others^a	Reference		Reference
PGA and BB	0.717 (0.553 0.929)	0.0118	0.788 (0.57 1.091)	0.1508
PGA and CAI	0.704 (0.485 1.021)	0.0642	0.81 (0.513 1.28)	0.3678
CAI and BB	1.181 (0.806 1.731)	0.3936	1.082 (0.671 1.744)	0.7461
PGA and BB and CAI	0.846 (0.496 1.444)	0.5406	0.871 (0.441 1.722)	0.692

^aOthers included the following: α-blocker, α-agonist, rho kinase inhibitor, osmotic diuretic and autonomic agent BB, β blocker; CAI, carbonic anhydrase inhibitor; CI, confidence interval; HR, hazard ratio; PGA, prostaglandin analog

ISSN: 1471-2415